X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2164) 2164
Book Review (283) 283
Publication (161) 161
Conference Proceeding (7) 7
Book Chapter (4) 4
Dissertation (3) 3
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1949) 1949
humans (1831) 1831
topotecan (1470) 1470
oncology (1447) 1447
female (1378) 1378
topotecan - administration & dosage (960) 960
middle aged (897) 897
aged (824) 824
chemotherapy (802) 802
adult (792) 792
male (791) 791
antineoplastic combined chemotherapy protocols - therapeutic use (708) 708
cancer (634) 634
ovarian neoplasms - drug therapy (458) 458
treatment outcome (455) 455
cisplatin (410) 410
camptothecin - analogs & derivatives (399) 399
drug administration schedule (397) 397
animals (396) 396
topotecan - adverse effects (390) 390
antineoplastic agents - administration & dosage (389) 389
pharmacology & pharmacy (366) 366
antineoplastic agents - therapeutic use (363) 363
paclitaxel (362) 362
lung neoplasms - drug therapy (328) 328
topotecan - therapeutic use (324) 324
antineoplastic combined chemotherapy protocols - adverse effects (312) 312
ovarian cancer (303) 303
carcinoma (301) 301
neoplasm recurrence, local - drug therapy (298) 298
dose-response relationship, drug (277) 277
mice (274) 274
camptothecin (270) 270
camptothecin - administration & dosage (257) 257
aged, 80 and over (253) 253
cisplatin - administration & dosage (249) 249
paclitaxel - administration & dosage (247) 247
trial (247) 247
antineoplastic agents - adverse effects (241) 241
care and treatment (240) 240
infusions, intravenous (240) 240
phase-ii (234) 234
neoplasms - drug therapy (227) 227
antineoplastic combined chemotherapy protocols - administration & dosage (223) 223
topotecan - pharmacokinetics (221) 221
carboplatin (211) 211
irinotecan (211) 211
carboplatin - administration & dosage (210) 210
obstetrics & gynecology (209) 209
etoposide (207) 207
drug resistance, neoplasm (206) 206
disease-free survival (203) 203
pharmacokinetics (203) 203
research (202) 202
solid tumors (200) 200
phase-i (198) 198
antineoplastic agents - pharmacokinetics (192) 192
cell line, tumor (184) 184
medicine & public health (184) 184
therapy (184) 184
survival rate (179) 179
child (173) 173
topoisomerase i inhibitors (171) 171
ovarian neoplasms - pathology (170) 170
topotecan - pharmacology (170) 170
neoplasm staging (166) 166
cyclophosphamide (165) 165
etoposide - administration & dosage (165) 165
child, preschool (161) 161
adolescent (160) 160
antineoplastic agents (158) 158
survival analysis (158) 158
doxorubicin - administration & dosage (155) 155
tumors (154) 154
administration, oral (153) 153
retrospective studies (152) 152
cell lung-cancer (149) 149
drug therapy (149) 149
hematology (149) 149
hematology, oncology and palliative medicine (149) 149
lung neoplasms - pathology (148) 148
antineoplastic agents - pharmacology (146) 146
camptothecin - therapeutic use (146) 146
combination (142) 142
analysis (141) 141
antimitotic agents (141) 141
carcinoma, small cell - drug therapy (141) 141
doxorubicin (141) 141
gynecologic-oncology-group (140) 140
topoisomerase-i (137) 137
clinical trials (136) 136
combined modality therapy (133) 133
prognosis (132) 132
toxicity (132) 132
deoxycytidine - analogs & derivatives (129) 129
camptothecin - adverse effects (125) 125
camptothecin - pharmacokinetics (121) 121
pharmacology/toxicology (120) 120
salvage therapy (119) 119
gemcitabine (115) 115
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2112) 2112
French (15) 15
Japanese (12) 12
Chinese (11) 11
Italian (8) 8
Hungarian (4) 4
Polish (3) 3
Portuguese (2) 2
German (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2017, Volume 35, Issue 29, pp. 3347 - 3353
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2002, Volume 94, Issue 24, pp. 1883 - 1888
The prescribed dose of anticancer agents is most commonly calculated using body surface area as the only independent variable, and it has been shown that this... 
TOPOISOMERASE-I INHIBITOR | INTRAVENOUS CISPLATIN | DOSE-ESCALATION | ADVANCED SOLID TUMORS | ONCOLOGY | ORAL TOPOTECAN | MATRIX-METALLOPROTEINASE INHIBITOR | SCHEDULE | CLINICAL PHARMACOKINETICS | PHASE-I | CREMOPHOR EL | Cytosine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Drugs, Investigational - pharmacokinetics | Cytosine - administration & dosage | Male | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - administration & dosage | Uracil - administration & dosage | Dacarbazine - analogs & derivatives | Adult | Dacarbazine - pharmacokinetics | Dioxolanes - pharmacokinetics | Female | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Body Surface Area | Paclitaxel - administration & dosage | Dacarbazine - administration & dosage | Cytosine - pharmacokinetics | Drug Administration Schedule | Docosahexaenoic Acids - administration & dosage | Docosahexaenoic Acids - pharmacokinetics | Drugs, Investigational - administration & dosage | Dioxolanes - administration & dosage | Infusions, Intravenous | Temozolomide | Fluorouracil - pharmacokinetics | Uracil - pharmacokinetics | Clinical Trials, Phase I as Topic | Uracil - analogs & derivatives | Antimitotic agents | Drug metabolism | Dosage and administration | Testolactone | Antineoplastic agents | Analysis | Studies | Medical research | Adults | History | Cancer | Index Medicus
Journal Article
European Journal of Haematology, ISSN 0902-4441, 03/2010, Volume 84, Issue 3, pp. 266 - 270
Few diseases have a prognosis worse than Hodgkin's lymphoma (HL), patients relapsing after autologous or allogeneic stem cell transplantation. Here, we report... 
Cyclophosphamide | Transplantation | Dexamethasone | Refractory disease | Thalidomide | Hodgkin's lymphoma | dexamethasone | refractory disease | THERAPY | thalidomide | RECURRENT | transplantation | DISEASE | cyclophosphamide | VINBLASTINE | PATIENT | HEMATOLOGY | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prednisolone - administration & dosage | Humans | Salvage Therapy | Drug Resistance, Neoplasm | Male | Transplantation, Autologous | Vinblastine - administration & dosage | Hodgkin Disease - surgery | Cisplatin - administration & dosage | Hodgkin Disease - radiotherapy | Organoplatinum Compounds - administration & dosage | Hodgkin Disease - drug therapy | Vincristine - administration & dosage | Adult | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Antibodies, Monoclonal, Murine-Derived | Dexamethasone - administration & dosage | Deoxycytidine - administration & dosage | Rituximab | Etoposide - administration & dosage | Combined Modality Therapy | Vidarabine - analogs & derivatives | Bleomycin - administration & dosage | Thalidomide - administration & dosage | Remission Induction | Cytarabine - administration & dosage | Melphalan - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Topotecan - administration & dosage | Mechlorethamine - administration & dosage | Vidarabine - administration & dosage | Peripheral Blood Stem Cell Transplantation | Deoxycytidine - analogs & derivatives | Carmustine - administration & dosage | Antimitotic agents | Stem cells | Antineoplastic agents | Hodgkin's disease | Steroids | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 13, pp. 1309 - 1316
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2014, Volume 20, Issue 8, pp. 2104 - 2114
Purpose: When evaluated in patients with ovarian and other cancer, vintafolide (EC145), a potent folate-targeted vinca alkaloid conjugate, displayed a toxicity... 
OVEREXPRESSION | ONCOLOGY | FOLATE RECEPTOR EXPRESSION | PHASE-II | CONJUGATE | TISSUES | INHIBITORS | ANTITUMOR-ACTIVITY | CELL-LINES | CANCER | EPITHELIAL OVARIAN-CARCINOMA | Folic Acid - pharmacology | Paclitaxel - pharmacology | Taxoids - pharmacology | Humans | Antineoplastic Agents - administration & dosage | Folic Acid - administration & dosage | Cisplatin - administration & dosage | Dose-Response Relationship, Drug | Neoplasms, Experimental - pathology | Vinca Alkaloids - administration & dosage | Vinca Alkaloids - pharmacology | Camptothecin - administration & dosage | Mice, Inbred DBA | Antineoplastic Agents - pharmacology | Paclitaxel - administration & dosage | Camptothecin - analogs & derivatives | Doxorubicin - administration & dosage | Folic Acid - analogs & derivatives | Topotecan - pharmacology | Carboplatin - administration & dosage | Treatment Outcome | Cisplatin - pharmacology | Neoplasms - drug therapy | Drug Synergism | Xenograft Model Antitumor Assays | Taxoids - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice, Nude | Cell Line, Tumor | Topotecan - administration & dosage | Cell Proliferation - drug effects | Mice, Inbred BALB C | HeLa Cells | Carboplatin - pharmacology | Neoplasms - pathology | Camptothecin - pharmacology | Neoplasms, Experimental - drug therapy | Doxorubicin - pharmacology | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2017, Volume 23, Issue 21, pp. 6441 - 6449
Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a... 
INTERLEUKIN-2 | MELANOMA | SOLID TUMORS | REFRACTORY NEUROBLASTOMA | ONCOLOGY | PHASE-I TRIAL | CYCLOPHOSPHAMIDE | IMMUNOTHERAPY | RECURRENT | CELLULAR CYTOTOXICITY | PLUS | Drug-Related Side Effects and Adverse Reactions - blood | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Neuroblastoma - blood | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Infant | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Neoplasm Recurrence, Local - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Dacarbazine - analogs & derivatives | Killer Cells, Natural - immunology | Camptothecin - administration & dosage | Female | Child | Neoplasm Recurrence, Local - blood | Neuroblastoma - pathology | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Dacarbazine - administration & dosage | Gangliosides - antagonists & inhibitors | Interleukin-2 Receptor alpha Subunit - blood | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Combined Modality Therapy | Cell- and Tissue-Based Therapy | Gangliosides - immunology | Disease-Free Survival | Ifosfamide - administration & dosage | Neuroblastoma - drug therapy | Adolescent | Topotecan - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Interleukin-2 - blood | Toxicity | Cytotoxicity | Malignancy | Neuroblastoma | Cerebrospinal fluid | Pain | Interleukin 2 | Surgery | Myelosuppression | Children | Natural killer cells | Antibody-dependent cell-mediated cytotoxicity | Thrombocytopenia | Immune response | Cytokines | Ifosfamide | Granulocyte-macrophage colony-stimulating factor | Hypersensitivity | Etoposide | Pharmacology | Patients | Irinotecan | Cyclophosphamide | Chemotherapy | Experimental design | Monoclonal antibodies | Carboplatin | Temozolomide | Pharmacokinetics | Cancer | Index Medicus
Journal Article
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 09/2011, Volume 71, Issue 17, pp. 5626 - 5634
Journal Article
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 10/2017, Volume 69, Issue 10, pp. 1318 - 1326
ObjectivesThis work aimed to evaluate semisolid formulations containing topotecan (TPT) loaded nanostructured lipid carriers (NLC) for topical treatment of... 
hydroxyethylcellulose gel | nanostructured lipid carriers | cytotoxicity and skin permeation | chitosan gel | topotecan | PHARMACOLOGY & PHARMACY | Skin Absorption - physiology | Topoisomerase I Inhibitors - metabolism | Skin Neoplasms - drug therapy | Melanoma, Experimental - drug therapy | Drug Carriers - administration & dosage | Melanoma, Experimental - metabolism | Topotecan - metabolism | Antineoplastic Agents - administration & dosage | Antineoplastic Agents - metabolism | Dose-Response Relationship, Drug | Swine | Hydrogels - administration & dosage | Nanoparticles - metabolism | Skin Absorption - drug effects | Hydrogels - metabolism | Cell Survival - physiology | Organ Culture Techniques | Cell Survival - drug effects | Drug Carriers - metabolism | Topoisomerase I Inhibitors - administration & dosage | Treatment Outcome | Lipids - administration & dosage | Skin Neoplasms - metabolism | Animals | Topotecan - administration & dosage | Mice | Nanoparticles - administration & dosage | Administration, Topical | Nanoparticles | Chemotherapy | Dermatology | Melanoma | Formulae, receipts, prescriptions | Cellulose | Dermatologic agents | Skin | Drug therapy | Skin cancer | Cancer | Formulations | Cell culture | Gels | Hydrogels | Toxicity | Cytotoxicity | Topotecan | Dispersions | Penetration | Chitosan | Semisolids | Tumors | Index Medicus
Journal Article